No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Shares in Angle tanked on Wednesday after the cancer treatment tech group delivered a cautious outlook, pointing to only "modest" growth compared with the 31% surge in revenues seen in 2024.
The company, whose technology harvests circulating tumour cell (CTC) from the blood for analysis, reported strong annual results for last year, with revenues jumping to 2.9 from 2.2m in 2023, while losses shrank by 29% to 14.2m.
However, in its outlook statement, Angle said that recent market turbulence, the uncertain macro environment and further reductions to research funding across academic and government labs has "adversely impacted the company's year-to-date revenues".
Discussions are progressing with existing and new large pharma customers and medtech diagnostics companies, but it is unclear when these opportunities will convert to revenues.
"We have multiple large opportunities actively under discussion. However, these are binary in nature and their timing is uncertain. Modest growth in 2025 revenues compared to 2024 is anticipated and there is the potential, dependent on the large opportunities under discussion, for this to be exceeded," the company said.
Shares were down 17% at 8.11p by 1108 BST.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.